NASDAQ · MYNZ
Mainz Biomed B.V.
$3.59+$0.03 (+0.84%)
Mainz Biomed B.V.’s quoted price sits in the upper half of its reported 52-week range, 32.77% below the high.
Loading market information…
NASDAQ · CHEK · USD
Stock price, earnings
Quote as of May 21, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Check-Cap Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Check-Cap Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Check-Cap Ltd. is an Israeli medical diagnostics company currently in the clinical development phase. It is dedicated to advancing a novel capsule-based screening method that employs ultra-low-dose X-rays. This technology is designed to thoroughly examine the internal surface of the colon, aiming to identify precancerous polyps and other structural irregularities. The company's primary offering, the C-Scan system, is composed of three integral parts: the C-Scan Cap, an ingestible X-ray scanning capsule for detecting suspected polyps; the C-Scan Track, a disposable unit that adheres to the patient's back via biocompatible adhesive patches; and the C-Scan View software. This client/server application enables the download of procedural data from the C-Scan Track, performs detailed analysis, and generates comprehensive reports. Check-Cap Ltd. was founded in 2004 and operates from its headquarters in Isfiya, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.59+$0.03 (+0.84%)
Mainz Biomed B.V.’s quoted price sits in the upper half of its reported 52-week range, 32.77% below the high.
$0.93+$0.05 (+5.09%)
Biofrontera Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.89% below the high.
$5.05+$1.34 (+36.12%)
Adial Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.41% below the high.
$0.83-$0.03 (-3.43%)
Lucyd, Inc’s quoted price sits in the lower half of its reported 52-week range, 58.89% below the high.
$3.33+$0.22 (+7.07%)
Sunshine Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.28% below the high.
$1.07$0.00 (0.0%)
Acurx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.81% below the high.
$2.13-$0.23 (-9.75%)
NeuroSense Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 91.61% below the high.
$0.77+$0.01 (+0.69%)
Profusa, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 99.96% below the high.
